{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:59:26Z","timestamp":1791496766812,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. We previously reported that the prevalence of phospholipase A2 receptor (PLA2R)- and thrombospondin type 1 domain containing 7A (THSD7A)-associated MN patients in Japan is 52.7% and 9.1%, respectively. In addition to PLA2R and THSD7A, we assessed the presence of newly discovered target antigens, neural epidermal growth factor-like 1 (NELL-1), semaphorin 3B (SEMA3B), and exostosin 1\/exostosin 2 (Ext1\/Ext2), in renal specimens from patients with primary and secondary MN by immunohistochemistry. We found enhanced glomerular staining of PLA2R, THSD7A, NELL-1, and Ext1\/Ext2 in 53.6%, 8.7%, 1.5%, and 13.0% of the renal samples, respectively, in patients with primary MN. None of the patient specimens showed enhanced staining of SEMA3B. Enhanced glomerular staining of PLA2R, NELL-1, and Ext1\/Ext2 was detected in 5.7%, 8.6%, and 22.9% of the patients with secondary MN, respectively. Based on our findings, we recommend the assessment of PLA2R, THSD7A and NELL-1 in addition to clinical information and IgG4 staining to differentiate between primary and secondary MN. This would aid in distinguishing secondary MN patients from primary MN patients who coincidentally have some secondary characteristics.<\/jats:p>","DOI":"10.1038\/s41598-022-07037-2","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T11:02:51Z","timestamp":1645527771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prevalence of neural epidermal growth factor-like 1- and exostosin 1\/exostosin 2-associated membranous nephropathy: a single-center retrospective study in Japan"],"prefix":"10.1038","volume":"12","author":[{"given":"Takamasa","family":"Iwakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Ema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naro","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"7037_CR1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/ASN.2005010028","volume":"16","author":"D Cattran","year":"2005","unstructured":"Cattran, D. Management of membranous nephropathy: When and what for treatment. J. Am. Soc. Nephrol. 16, 1188\u20131194 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7037_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1681\/ASN.2009121220","volume":"21","author":"P Ronco","year":"2010","unstructured":"Ronco, P. & Debiec, H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J. Am. Soc. Nephrol. 21, 564\u2013569 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7037_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1172\/JCI85265","volume":"126","author":"NM Tomas","year":"2016","unstructured":"Tomas, N. M. et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J. Clin. Invest. 126, 2519\u20132532 (2016).","journal-title":"J. Clin. Invest."},{"key":"7037_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","volume":"97","author":"C Meyer-Schwesinger","year":"2020","unstructured":"Meyer-Schwesinger, C. et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int. 97, 913\u2013919 (2020).","journal-title":"Kidney Int."},{"key":"7037_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","volume":"97","author":"S Sethi","year":"2020","unstructured":"Sethi, S. et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 97, 163\u2013174 (2020).","journal-title":"Kidney Int."},{"key":"7037_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","volume":"98","author":"S Sethi","year":"2020","unstructured":"Sethi, S. et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 98, 1253\u20131264 (2020).","journal-title":"Kidney Int."},{"key":"7037_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1681\/ASN.2018080852","volume":"30","author":"S Sethi","year":"2019","unstructured":"Sethi, S. et al. Exostosin 1\/Exostosin 2-associated membranous nephropathy. J. Am. Soc. Nephrol. 30, 1123\u20131136 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7037_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra, J. M., Beck, L. H. Jr., Beck, D. M., Wetzels, J. F. & Salant, D. J. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286\u20131291 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"7037_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin, W. et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137\u20131143 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7037_CR10","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","volume":"26","author":"E Hoxha","year":"2011","unstructured":"Hoxha, E. et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol. Dial. Transplant. 26, 2526\u20132532 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"7037_CR11","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","volume":"23","author":"JM Hofstra","year":"2012","unstructured":"Hofstra, J. M. et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1735\u20131743 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7037_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","volume":"82","author":"E Hoxha","year":"2012","unstructured":"Hoxha, E. et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 82, 797\u2013804 (2012).","journal-title":"Kidney Int."},{"key":"7037_CR13","doi-asserted-by":"publisher","first-page":"62151","DOI":"10.1371\/journal.pone.0062151","volume":"8","author":"YJ Oh","year":"2013","unstructured":"Oh, Y. J., Yang, S. H., Kim, D. K., Kang, S. W. & Kim, Y. S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS\u00a0One 8, 62151. https:\/\/doi.org\/10.1371\/journal.pone.0062151 (2013).","journal-title":"PLoS\u00a0One"},{"key":"7037_CR14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","volume":"28","author":"B Svobodova","year":"2013","unstructured":"Svobodova, B., Honsova, E., Ronco, P., Tesar, V. & Debiec, H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol. Dial. Transplant. 28, 1839\u20131844 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"7037_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10157-014-1054-2","volume":"19","author":"S Akiyama","year":"2015","unstructured":"Akiyama, S. et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin. Exp. Nephrol. 19, 653\u20136012 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"7037_CR16","first-page":"353","volume":"34","author":"A Segarra-Medrano","year":"2014","unstructured":"Segarra-Medrano, A. et al. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrologia 34, 353\u2013359 (2014).","journal-title":"Nefrologia"},{"key":"7037_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","volume":"83","author":"D Kanigicherla","year":"2013","unstructured":"Kanigicherla, D. et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 83, 940\u2013948 (2013).","journal-title":"Kidney Int."},{"key":"7037_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","volume":"364","author":"H Debiec","year":"2011","unstructured":"Debiec, H. & Ronco, P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N. Engl. J. Med. 364, 689\u2013690 (2011).","journal-title":"N. Engl. J. Med."},{"key":"7037_CR19","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277\u20132287 (2014).","journal-title":"N. Engl. J. Med."},{"key":"7037_CR20","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco, P. & Debiec, H. Pathophysiological advances in membranous nephropathy: Time for a shift in patient\u2019s care. Lancet 385, 1983\u20131992 (2015).","journal-title":"Lancet"},{"key":"7037_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrneph.2012.35","volume":"8","author":"P Ronco","year":"2012","unstructured":"Ronco, P. & Debiec, H. Pathogenesis ofmembranous nephropathy: Recent advances and future challenges. Nat. Rev. Nephrol. 8, 203\u2013213 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"7037_CR22","doi-asserted-by":"publisher","first-page":"e0138841","DOI":"10.1371\/journal.pone.0138841","volume":"10","author":"T Iwakura","year":"2015","unstructured":"Iwakura, T., Ohashi, N., Kato, A., Baba, S. & Yasuda, H. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of japanese patients with idiopathic membranous nephropathy. PLoS\u00a0One 10, e0138841. https:\/\/doi.org\/10.1371\/journal.pone.0138841 (2015).","journal-title":"PLoS\u00a0One"},{"key":"7037_CR23","doi-asserted-by":"publisher","first-page":"e0158154","DOI":"10.1371\/journal.pone.0158154","volume":"11","author":"K Hihara","year":"2016","unstructured":"Hihara, K. et al. Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy. PLoS\u00a0One 11, e0158154. https:\/\/doi.org\/10.1371\/journal.pone.0158154 (2016).","journal-title":"PLoS\u00a0One"},{"key":"7037_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00428-019-02558-0","volume":"474","author":"S Hara","year":"2019","unstructured":"Hara, S. et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virch. Arch. 474, 735\u2013743 (2019).","journal-title":"Virch. Arch."},{"key":"7037_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10157-019-01712-x","volume":"23","author":"H Koga","year":"2019","unstructured":"Koga, H. et al. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA. Clin. Exp. Nephrol. 23, 465\u2013473 (2019).","journal-title":"Clin. Exp. Nephrol."},{"key":"7037_CR26","doi-asserted-by":"publisher","first-page":"611317","DOI":"10.3389\/fmed.2020.611317","volume":"7","author":"G Moroni","year":"2020","unstructured":"Moroni, G. & Ponticelli, C. Secondary membranous nephropathy. A narrative review. Front. Med. (Lausanne) 7, 611317 (2020).","journal-title":"Front. Med. (Lausanne)"},{"key":"7037_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1053\/j.ajkd.2020.04.013","volume":"76","author":"N Hanset","year":"2020","unstructured":"Hanset, N. et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: A retrospective multicenter cohort study. Am. J. Kidney Dis. 76, 624\u2013635 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"7037_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","volume":"99","author":"T Caza","year":"2021","unstructured":"Caza, T. et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 99, 967\u2013976 (2021).","journal-title":"Kidney Int."},{"key":"7037_CR29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","volume":"374","author":"E Hoxha","year":"2016","unstructured":"Hoxha, E. et al. A mechanism for cancer-associated membranous nephropathy. N. Engl. J. Med. 374, 1995\u20131996 (2016).","journal-title":"N. Engl. J. Med."},{"key":"7037_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","volume":"28","author":"E Hoxha","year":"2017","unstructured":"Hoxha, E. et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J. Am. Soc. Nephrol. 28, 520\u2013531 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7037_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.xkme.2021.03.013","volume":"3","author":"T Iwakura","year":"2021","unstructured":"Iwakura, T. et al. Primary membranous nephropathy with enhanced staining of exostosin 1\/exostosin 2 in the glomeruli: A report of 2 cases. Kidney Med. 3, 669\u2013673. https:\/\/doi.org\/10.1016\/j.xkme.2021.03.013 (2021).","journal-title":"Kidney Med."},{"key":"7037_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000364782","volume":"40","author":"N Leeaphorn","year":"2014","unstructured":"Leeaphorn, N. et al. Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies. Am. J. Nephrol. 40, 29\u201335 (2014).","journal-title":"Am. J. Nephrol."},{"key":"7037_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.ajkd.2007.06.003","volume":"50","author":"R Bj\u00f8rneklett","year":"2007","unstructured":"Bj\u00f8rneklett, R. et al. Long-term risk of cancer in membranous nephropathy patients. Am. J. Kidney Dis. 50, 396\u2013403 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"7037_CR34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100, S1\u2013S276 (2021).","journal-title":"Kidney Int."},{"key":"7037_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2, 139\u2013274 (2012).","journal-title":"Kidney Int. Suppl."},{"key":"7037_CR36","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1523-1755.2004.00518.x","volume":"65","author":"H Shiiki","year":"2004","unstructured":"Shiiki, H. et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 65, 1400\u20131407 (2004).","journal-title":"Kidney Int."},{"key":"7037_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271 (1982).","journal-title":"Arthritis Rheum."},{"key":"7037_CR38","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum. 40, 1725 (1997).","journal-title":"Arthritis Rheum."},{"key":"7037_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.xkme.2019.05.004","volume":"1","author":"RS Niznik","year":"2019","unstructured":"Niznik, R. S. et al. Global glomerulosclerosis in kidney biopsies with differing amounts of cortex: A clinical-pathologic correlation study. Kidney Med. 1, 153\u2013161 (2019).","journal-title":"Kidney Med."},{"key":"7037_CR40","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari, F. et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J. Am. Soc. Nephrol. 32, 972\u2013982 (2021).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07037-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:07:35Z","timestamp":1669331255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07037-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7037"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07037-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2967"}}